ATE276366T1 - Type f botulinum toxin und seine verwendung - Google Patents

Type f botulinum toxin und seine verwendung

Info

Publication number
ATE276366T1
ATE276366T1 AT96917600T AT96917600T ATE276366T1 AT E276366 T1 ATE276366 T1 AT E276366T1 AT 96917600 T AT96917600 T AT 96917600T AT 96917600 T AT96917600 T AT 96917600T AT E276366 T1 ATE276366 T1 AT E276366T1
Authority
AT
Austria
Prior art keywords
toxin
type
botulinum toxin
fragment
fusion protein
Prior art date
Application number
AT96917600T
Other languages
English (en)
Inventor
Michael James Elmore
Margaret Lamble Mauchline
Nigel Peter Minton
Vladimir Artymovich Pasechnik
Richard William Titball
Original Assignee
Health Prot Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Prot Agency filed Critical Health Prot Agency
Application granted granted Critical
Publication of ATE276366T1 publication Critical patent/ATE276366T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96917600T 1995-06-12 1996-06-12 Type f botulinum toxin und seine verwendung ATE276366T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9511909.5A GB9511909D0 (en) 1995-06-12 1995-06-12 Vaccine
PCT/GB1996/001409 WO1996041881A1 (en) 1995-06-12 1996-06-12 Type f botulinum toxin and use thereof

Publications (1)

Publication Number Publication Date
ATE276366T1 true ATE276366T1 (de) 2004-10-15

Family

ID=10775930

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96917600T ATE276366T1 (de) 1995-06-12 1996-06-12 Type f botulinum toxin und seine verwendung

Country Status (12)

Country Link
US (1) US7041792B2 (de)
EP (1) EP0833919B1 (de)
JP (1) JP4005633B2 (de)
AT (1) ATE276366T1 (de)
AU (1) AU705944B2 (de)
CA (1) CA2224444C (de)
DE (1) DE69633389T2 (de)
DK (1) DK0833919T3 (de)
ES (1) ES2224171T3 (de)
GB (1) GB9511909D0 (de)
PT (1) PT833919E (de)
WO (1) WO1996041881A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
DE19735105A1 (de) * 1997-08-13 1999-03-04 Univ Albert Ludwigs Freiburg Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen
AU4641299A (en) * 1998-07-22 2000-02-14 Agricultural Research Council Vaccine comprising a non-toxic immunogenic derivative of (clostridium botulinum)type d neurotoxin
CA2371279A1 (en) * 1999-05-12 2000-11-16 Leonard A. Smith Recombinant vaccine against botulinum neurotoxin
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
GB0525213D0 (en) * 2005-12-12 2006-01-18 Secr Defence Vaccine
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
KR102175159B1 (ko) * 2018-12-28 2020-11-05 대한민국 재조합 벡터, 형질전환 대장균, 보툴리눔 d/c형 중쇄 c말단 유래의 재조합 단백질을 포함하는 백신 조성물 및 키트

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
KR950702635A (ko) * 1992-07-31 1995-07-29 크리스틴 헬렌 수덴 감쇠 박테리아에서 재조합 융합 단백질의 발현(Expression of recombinant fusion proteins in attenuated bacteria)
GB9305919D0 (en) * 1993-03-22 1993-05-12 Health Lab Service Board Botulinum toxin polypeptides and their use as vaccines

Also Published As

Publication number Publication date
JP4005633B2 (ja) 2007-11-07
AU6012196A (en) 1997-01-09
ES2224171T3 (es) 2005-03-01
CA2224444C (en) 2010-02-16
AU705944B2 (en) 1999-06-03
EP0833919B1 (de) 2004-09-15
EP0833919A1 (de) 1998-04-08
DE69633389D1 (de) 2004-10-21
CA2224444A1 (en) 1996-12-27
JPH11507827A (ja) 1999-07-13
US20020081304A1 (en) 2002-06-27
US7041792B2 (en) 2006-05-09
PT833919E (pt) 2005-01-31
DE69633389T2 (de) 2005-10-27
DK0833919T3 (da) 2005-01-17
GB9511909D0 (en) 1995-08-09
WO1996041881A1 (en) 1996-12-27

Similar Documents

Publication Publication Date Title
FI974432A (fi) Grampositiivisten bakteerien käyttö rekombinanttiproteiinien ilmentämiseksi
BR9504791B1 (pt) composto de polipeptìdeo e composição farmacêutica.
IS4345A (is) Setin N-(indól-2-karbónýl)-b-alaninamíð, notkun þeirra og lyfjaefnablöndur
DE69434511D1 (de) Botulinumtoxin zur Behandlung von Dystonie
DZ2086A1 (fr) Benzylaminopipéridines substituées et compositionspharmaceutiques les contenant.
DK0643608T3 (da) Proteinrensning
ATE476495T1 (de) Bazillus thuringiensis und dessen insektizide proteine
DE69839566D1 (de) Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
ATE213639T1 (de) Proteinreinigung
KR950700990A (ko) 신규의 분비단백질 에프-스폰딘의 클로닝, 발현 및 용도
DE69625506D1 (de) Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung
ATE276366T1 (de) Type f botulinum toxin und seine verwendung
FR2694296B1 (fr) Peptides inhibant l'activité des protéines ras, préparation et utilisation.
KR950702242A (ko) 사포린 함유 단백질의 재조합 생산방법(Recombinant production of saporin-containing proteins)
DE68917837D1 (de) Peptid-Verbindungen.
NO980296D0 (no) Forbedrede terapeutiske midler
DE19681439T1 (de) Modifizierung von Polypeptidarzneimitteln zur Erhöhung des Elektrotransportflusses
FR2732978B1 (fr) Vecteur viral recombinant, composition pharmaceutique le contenant et cellules transformees correspondantes
ES2089784T3 (es) Expresion de estafilocinasas sin peptido de señal.
FI953422A0 (fi) Autolysoivia fuusioproteiineja hyväksikäyttävät ilmentämisjärjestelmät ja uusi pelkistävä polypeptidi
ATE309359T1 (de) Epil/plazentin
DK75393D0 (da) Production of protein
NO944025D0 (no) Forbedret fremstilling av rekombinant protein
NO944981D0 (no) Rensing av kringleholdige proteiner, spesielt t-PA
FR2718028B1 (fr) Nouvelles compositions cosmétiques ou dermopharmaceutiques contenant des hydrolysats peptidiques modifiés.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0833919

Country of ref document: EP

EEIH Change in the person of patent owner